Agios Pharmaceuticals, Inc.
) announced new encouraging data from the ongoing phase I study on
candidate, AG-221, among patients suffering from IDH2 mutant
positive hematologic malignancies.
The data was presented at the European Hematology Association
(EHA) in Italy. The new data confirmed the previously presented
data on AG-221's clinical activity, safety profile and unique
mechanism of action.
It was observed in the study that AG-221 showed favorable drug
exposure and pharmacokinetics at all doses tested with substantial
reductions in plasma levels of the oncometabolite
2-hydroxyglutarate (2HG). Moreover, it was observed that AG-221 was
We note that AG-221 is one of the most advanced candidates in
Agios' pipeline. The candidate is being evaluated for the treatment
of patients suffering from acute myelogenous leukemia (AML).
Based on promising safety and efficacy data from the studies so
far on AG-221, Agios plans to initiate four expansion cohorts in
the second half of 2014 - relapsed/refractory AML patients aged 60
years and above, relapsed/refractory AML patients aged under 60
years, untreated AML patients who decline standard of care
chemotherapy, and patients with other IDH2 mutant positive
hematologic malignancies (such as lymphoma, multiple myeloma,
Agios, a biopharmaceutical company, focuses on the treatment of
patients suffering from cancer and inborn errors of metabolism
The lead candidates in the cancer pipeline are AG-221 and
AG-120, targeting mutant isocitrate dehydrogenase 2 and 1 while the
lead candidate in the IEM program is AG-348.
Agios is developing AG-221 under a collaboration agreement with
Celgene recently exercised its exclusive option to license
AG-221, thereby gaining worldwide development and commercialization
rights for AG-221 while Agios continues to conduct early clinical
development and regulatory activities within the AG-221 development
Agios Pharma currently carries a Zacks Rank #3 (Hold). Investors
looking for better-ranked stocks in the healthcare sector may
consider companies like
). Both stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
AGIOS PHARMACT (AGIO): Free Stock Analysis
ALLERGAN INC (AGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis Report
To read this article on Zacks.com click here.